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Introduction: Lymphomatoid granulomatosis is an uncommon Epstein-Barr virus-positive B-cell lymphoma, an
angiocentric-destructive process with a predominant T-cell background. Lymphomatoid granulomatosis is listed
among rare diseases. Common localization is in the lungs. Lymphomatoid granulomatosis with oral involvement is
described in only two reports. In this report, we describe a third case of oral lymphomatoid granulomatosis.
Case presentation: A 65-year-old Caucasian man with a gingival ulceration underwent a biopsy. The histological
pattern was compatible with a grade III lymphomatoid granulomatosis. The staging revealed a nodular lesion in the
lower lobe of his right lung. Our patient also presented with hemoptysis, an unusual and not reported clinical sign.
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy was performed every three
weeks for six cycles.
Conclusions: The pulmonary nodule and the gingival lesion disappeared. At eight-month follow-up, our patient is
disease-free. We wish to emphasize that the oral manifestation described was the first sign of the disease and
allowed for diagnosis. This case report adds to the medical literature for the particular clinical presentation of this
rare disease.
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Over 90 percent of humans are infected by Epstein-Barr
virus (EBV) and the infection persists for life. EBV in-
fection is associated with a number of malignancies and
can infect B cells, T cells and natural killer (NK) cells.
The head and neck region contains several compart-
ments (that is nasopharynx, nasal and paranasal sinuses
and so on) each of which is potentially affected by neo-
plastic lymphoid proliferation [1]. Lymphomatoid granu-
lomatosis (LYG) is an angiocentric-destructive process
characterized by EBV-infected B cells and T-cell reac-
tion. Common localizations are lungs and mediastinum
nodes. Less frequently, LYG has also been described in
other sites. Oral localization is very infrequent. In the
scientific literature, we found that LYG with oral in-
volvement in immune-competent individuals has only
been described in two reports: a palatal involvement, a* Correspondence: tommaso.cutilli@cc.univaq.it
1Department of Life, Health & Environmental Sciences - Maxillofacial Surgery
Operative Unit and Postgraduate School of Maxillofacial Surgery, University
of L'Aquila, Via della Comunità Europea, 13, 67100 L’Aquila, Italy
Full list of author information is available at the end of the article
© 2014 Cargini et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.local recurrence of primary pulmonary LYG [2]; and a
gingival lesion, the only site of the disease, considered an
atypical form [3]. We describe the third case of LYG
with oral involvement and we wish to emphasize that
the oral manifestation described was the first sign of the
disease and allowed for the diagnosis of the simultan-
eous pulmonary LYG.Case presentation
A Caucasian 65-year-old man, suffering for a month
from a persistent pain in the inferior oral fornix and in
the symphysis region of the mandible, was hospitalized.
Our patient did not have a relevant medical history: no
use of tobacco, no alcohol abuse, no medications, no
weight loss. During an oral examination, very poor oral
hygiene was observed with severe widespread periodon-
tal disease, dental plaque, and several exposed dental
roots, especially in the inferior dental arch. In this con-
text, a severe gingival ulceration extending from the 3.1
to the 4.3 region was observed with mobility of teeth 4.1
and 4.2. The lesion showed granulomatous tissue, andLtd. This is an Open Access article distributed under the terms of the Creative
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ported severe pain on palpation. No laterocervical nodes
were present. Limited local bone resorption of the alveo-
lar process was observed on standard radiologic examin-
ation (panoramic radiography) (Figure 1b). His routine
laboratory test results were negative. A biopsy was per-
formed immediately and our patient was discharged
from the department with antibiotics (clavulanic acid
125mg and amoxicillin 875mg twice a day) and a pre-
scription for nonsteroidal anti-inflammatory drugs. The
histological report described a rich inflammatory infil-
trate of CD3-, CD4- and CD8-positive small T cells,
CD30-positive B cells, and a low number of CD56- and
CD57-positive natural killer (NK) cells. The lymphopro-
liferative foci, CD20+, appeared to have angiocentric
necrotizing blasts and high positivity for latent mem-
brane protein 1 (LMP1) and EBV protein gene 3, com-
patible with grade III LYG (Figure 2). Our patient was
immediately recalled and a total-body computed tomog-
raphy (TBCT) scan with intravenous contrast enhance-
ment was performed. The study of the mandible showed
osteitis of the anterior arch characterized by thickening
of the spongiosa (Figure 3a); it also showed irregular bone
resorption at the site of the gingival lesion (Figure 3b).
The TBCT scan detected a nodular lesion (13×14 mm) in
the lower lobe of his right lung, described as a ‘cannonball’,Figure 1 The course of the clinical presentation of the oral lymphom
to bleed gingival ulceration with granulomatous tissue, dental root exposu
panoramic radiography shows mandibular alterations in the area of the inc
ridge (thin black arrow). Axial computed tomography scans shows osteitis
colonization. (d) At eight-month follow-up: the granulomatous lesion has d
loss of tooth 4.2.which showed contrast enhancement due to profuse vas-
cularization. No mediastinic nodes were present but mul-
tiple nodes were present in his right axillary fossae and
peri-iliac veins bilaterally (Figure 4). No pathological en-
hancement was detected in his central nervous system
(CNS). Our patient was evaluated at the Medical Oncol-
ogy Service and began chemotherapy (ChT) treatment. In
the meantime, the gingival ulceration had grown, with
bacterial colonization (Figure 1b). Our patient also repor-
ted several episodes of hemoptysis. According to guide-
lines [2-6], rituximab, cyclophosphamide, doxorubicin,
vincristine, and prednisone (R-CHOP), the ChT scheme,
was administrated every three weeks for six cycles. A re-
staging with a TBCT scan was performed, respectively,
after four cycles, six cycles and after eight months. The
pulmonary nodule and the gingival lesion disappeared
(Figures 4b,1d). The patient at the time of this writing
was disease-free.
Discussion
Lymphomatoid granulomatosis is an EBV-positive large
B-cell lymphoma angiocentric-destructive process/dis-
order/disease with a predominant T-cell background,
which is characterized by prominent pulmonary involve-
ment; extra pulmonary sites described are kidneys, liver,
skin and the CNS. LYG was first described by Leibow inatoid granulomatosis before and after therapy. (a) Reddened, easy
re and mobility of teeth 4.1 and 4.2. (b) Radiological evaluation:
isors (black arrow) and resorption of the right incisor-canine alveolare
(black arrow). (c) The gingival ulceration has extended, with bacterial
isappeared; the gingival inflammation persists with the spontaneous
Figure 2 Histologic pattern of lymphomatoid granulomatosis: (a) (c) Rich B-cell blasts (hematoxylin and eosin 40×). Immunohistochemical
study: (b) wide expression of CD 20+ receptor (20×); (d) high positivity for latent membrane protein 1, expression of Epstein-Barr virus infection
in B cells and their activation (20×).
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triad: 1) nodular polymorphic lymphoid infiltrate by small
B cells, plasma cells and large atypical mononuclear
cells; 2) angiitis due a full-thickness infiltration of ves-
sels by lymphocytes; 3) granulomatosis with central ne-
crosis within the lymphoid nodules.Figure 3 Computed tomography axial scans of the mandible.
Computed tomography axial scans of the mandible show (a) the
aspect of the thickening osteitis of the anterior arch (black arrow)
and (b) the irregular bone resorption (white arrow).LYG is listed among rare diseases [8]. Relevant data re-
garding prevalence and race predilection are unavailable.
Elements that are known are the male/female ratio (2:1)
and the mean age at presentation (the fifth to sixth dec-
ade of life). LYG is progressive and fatal. The mortality
rate is estimated between 50 and 60 percent. A mean
survival of 14 months to two years from diagnosis has
been described in the literature [9]. Common signs of
lung localization are cough, dyspnea and chest pain, ob-
served in 54 to 80 percent of cases. Systemic involve-
ment with fever, sweating and weight loss is described in
30 to 70 percent of cases. Cutaneous manifestations are
observed in 36 to 53 percent of cases, consisting of ery-
thema, nodules and plaques. In CNS involvement, there
are deficit signs such as blindness, hemiparesis and ata-
xia in 10 to 35 percent of cases. Ulceration of the upper
airways is described in 10 percent of cases. Therefore,
LYG with oral involvement is a very rare event and oc-
curs in apparently immunocompetent young subjects
without modification of clinical and laboratory data.
There is evidence in LYG of defective immunosurveil-
lance with a low count of CD4/CD8 T cells. Due to the
angiocentric nature and extranodal localization, LYG is
confused with other angiocentric diseases such as NK/
T-cell lymphoma, but EBV-infected B-cells in LYG is the
main distinguishing factor of these two pathologic en-
tities [2]. The immunohistological feature is described in
the case presentation. The number of immunoblasts EBV
infected is related to the grade and prognosis of LYG.
Grade I lesions have a low number of atypical EBV + (<5
in high-power field) and necrosis areas are minimal. In
Figure 4 Total-body computed tomography scans with contrast
enhancement. Total-body computed tomography scans show: (a) a
nodular mass (a ‘cannonball’ - 13x14 mm) in the lower lobe of the
right lung (white arrow); (b) at eight-month follow-up, the scan
shows the disappearance of the pulmonary lesion.
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(from 5 to 20 in high-power field) and necrosis areas are
evident. In grade III, numerous atypical cells are identified
(>50 in high-power field) and necrosis areas are promin-
ent. Lower-grade (I to II) LYG occasionally show a spon-
taneous remission and the strategies applied to enhance
the host's underlying immune system are effective. Ac-
cording to guidelines of the World Health Organization
(WHO) classification, grade III LYG should be considered
to be diffuse large B-cell lymphoma (DLBCL) (either as a
not otherwise specified T cell/histiocyte-rich large B-cell
lymphoma, or EBV-positive DLBCL of older people, even-
tually associated with the intake of immunosuppressive
drugs) [10]. In some cases, it has an uncertain malignant
potential; in other cases, it has a poor prognosis.
The National Cancer Institute has recommended a
combination of immunotherapy and chemotherapy for
grade III LYG treatment. R-CHOP, given every three
weeks for six or eight cycles, is the chemotherapy scheme
followed. After four cycles, restaging with a TBCT scan is
necessary [11].Conclusions
LYG is a rare EBV-driven progressive lymphoprolifera-
tive disease. Epidemiological data are fragmented and in-
complete, thus diagnosis is very difficult and requires
correlation between clinical signs and histopathologic
pattern. Our aim in presenting this case, still in observa-
tion, is that of indicating the possibility that LYG can
begin in the oral cavity, and also of focusing attention
on two other particular aspects: First, the oral involve-
ment of LYG is a very rare event, but the gingival ulcer-
ation and its easy access has allowed for immediate
biopsy, the early diagnosis of LYG and the early discov-
ery of its pulmonary localization. It may be possible that
oral and lung lesions are concomitant manifestations of
LYG. Second, the unusual sign of hemoptysis - an alarm
bell for pulmonary disease - is common in all lesions
near bronchial ramifications and vessels, or indicates
cavitation. Only one study described hemoptysis associ-
ated with LYG but this work reports multiple large cavi-
tation areas of lung near the pulmonary artery [12].
Instead, in our report, a CT scan with contrast en-
hancement showed only one ‘cannonball’ nodule in the
middle field of the right inferior lobe, distant from the
bronchial lumen and major vessels, in absence of cavita-
tion. Hemoptysis, therefore, should not have been present
in the case we describe. However, one of the diagnostic
criteria of LYG is a full-thickness angiitis by lymphocytes
and it is possible to hypothesize that the angiitis is the
basis of hemoptysis. In conclusion, we wish to emphasize
that the oral manifestation described was the first sign of
the disease and allowed for diagnosis and for the simulta-
neous pulmonary localization.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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